Trevi Therapeutics, Inc. Depreciation
Trevi Therapeutics, Inc. (TRVI) reported Depreciation of $132.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-17
- Trevi Therapeutics, Inc. depreciation for the quarter ending 2022-12-31 was $15.00K, a 25.00% increase year-over-year.
- Trevi Therapeutics, Inc. depreciation for the quarter ending 2022-09-30 was $9.00K, a 30.77% decline year-over-year.
- Trevi Therapeutics, Inc. depreciation for the quarter ending 2022-06-30 was $8.00K, a 33.33% decline year-over-year.
- Trevi Therapeutics, Inc. depreciation for the quarter ending 2022-03-31 was $11.00K, a 15.38% decline year-over-year.
- Trevi Therapeutics, Inc. depreciation for fiscal 2025 was $132.00K, a 40.43% increase from fiscal 2024.
- Trevi Therapeutics, Inc. depreciation for fiscal 2024 was $94.00K, a 16.05% increase from fiscal 2023.
- Trevi Therapeutics, Inc. depreciation for fiscal 2023 was $81.00K, a 88.37% increase from fiscal 2022.
- Trevi Therapeutics, Inc. depreciation for fiscal 2022 was $43.00K, a 14.00% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $132.00K 10-K · filed 2026-03-17 | |||
| 2024-12-31 | $94.00K 10-K · filed 2026-03-17 | |||
| 2023-12-31 | $81.00K 10-K · filed 2025-03-18 | |||
| 2022-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $24.00K derived: sum of 2 quarters · filed 2024-03-20 | $32.00K derived: sum of 3 quarters · filed 2024-03-20 | $43.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $17.00K derived: sum of 2 quarters · filed 2022-11-10 | $28.00K 10-Q · filed 2022-11-10 | $40.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $19.00K 10-Q · filed 2022-08-11 | $31.00K derived: sum of 3 quarters · filed 2023-03-16 | $44.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-03-31 | $11.00K 10-Q · filed 2022-05-12 | $23.00K derived: sum of 2 quarters · filed 2023-03-16 | $36.00K derived: sum of 3 quarters · filed 2023-03-16 | $48.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $25.00K derived: sum of 2 quarters · filed 2023-03-16 | $37.00K derived: sum of 3 quarters · filed 2023-03-16 | $50.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $25.00K derived: sum of 2 quarters · filed 2022-11-10 | $38.00K 10-Q · filed 2022-11-10 | $51.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $25.00K 10-Q · filed 2022-08-11 | $38.00K derived: sum of 3 quarters · filed 2022-08-11 | $51.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $13.00K 10-Q · filed 2022-05-12 | $26.00K derived: sum of 2 quarters · filed 2022-05-12 | $39.00K derived: sum of 3 quarters · filed 2022-05-12 | $50.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $26.00K derived: sum of 2 quarters · filed 2022-03-17 | $37.00K derived: sum of 3 quarters · filed 2022-03-17 | $47.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $24.00K derived: sum of 2 quarters · filed 2021-11-10 | $34.00K 10-Q · filed 2021-11-10 | $43.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $21.00K 10-Q · filed 2021-08-12 | $30.00K derived: sum of 3 quarters · filed 2021-08-12 | $41.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $10.00K 10-Q · filed 2021-05-13 | $19.00K derived: sum of 2 quarters · filed 2021-05-13 | $30.00K derived: sum of 3 quarters · filed 2021-05-13 | $40.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $20.00K derived: sum of 2 quarters · filed 2021-03-25 | $30.00K derived: sum of 3 quarters · filed 2021-03-25 | $39.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $21.00K derived: sum of 2 quarters · filed 2020-11-12 | $30.00K 10-Q · filed 2020-11-12 | $43.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $19.00K 10-Q · filed 2020-08-13 | $32.00K derived: sum of 3 quarters · filed 2020-08-13 | $36.00K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $9.00K 10-Q · filed 2020-05-07 | $22.00K derived: sum of 2 quarters · filed 2020-05-07 | $26.00K derived: sum of 3 quarters · filed 2020-05-07 | $30.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $17.00K derived: sum of 2 quarters · filed 2020-03-16 | $21.00K derived: sum of 3 quarters · filed 2020-03-16 | $23.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $8.00K derived: sum of 2 quarters · filed 2019-11-14 | $10.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $6.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $2.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |